News Column

Research from University of Turku Yields New Findings on Cancer Gene Therapy

February 10, 2014



By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- New research on Biotechnology is the subject of a report. According to news reporting originating in Turku, Finland, by NewsRx journalists, research stated, "Decorin, a multifunctional small leucine-rich extracellular matrix proteoglycan, has been shown to possess potent antitumour activity. However, there is some uncertainty whether different cancer cells express decorin in addition to non-malignant stromal cells."

The news reporters obtained a quote from the research from the University of Turku, "In this study we clarified decorin expression by human bladder cancer cells both in vivo and in vitro. In addition, the effect of adenovirus-mediated decorin expression on human bladder cancer cells in vitro was examined. We first demonstrated using the publicly available GeneSapiens databank that decorin gene expression is present in both normal and malignant human bladder tissues. However, when we applied in situ hybridization with digoxigenin-labeled RNA probes for decorin on human bladder carcinoma tissue samples derived from a large radical cystectomy patient cohort (n=199), we unambiguously demonstrated that invasive and non-invasive bladder carcinoma cells completely lack decorin mRNA. The cancer cells were also negative for decorin immunoreactivity. Instead, decorin expression was localized solely to original non-malignant stromal areas of bladder tissue. In accordance with the aforementioned results, human bladder cancer cells in vitro were also negative for decorin expression as shown by RT-qPCR analyses. The lack of decorin expression by bladder cancer cells was shown not to be due to the methylation of the proximal promoter region of the decorin gene. When bladder cancer cells were transfected with a decorin adenoviral vector, their proliferation was significantly decreased."

According to the news reporters, the research concluded: "We have shown that human bladder cancer cells are totally devoid of decorin expression. We have also shown that adenovirus-mediated decorin gene transduction of human bladder cancer cell lines markedly inhibits their proliferation. Thus, decorin gene delivery offers new potential therapeutic tools in urothelial malignancies."

For more information on this research see: Lack of decorin expression by human bladder cancer cells offers new tools in the therapy of urothelial malignancies. Plos One, 2013;8(10):e76190. (Public Library of Science - www.plos.org; Plos One - www.plosone.org)

Our news correspondents report that additional information may be obtained by contacting A. Sainio, Dept. of Medical Biochemistry and Genetics, University of Turku, Turku, Finland. Additional authors for this research include M. Nyman, R. Lund, S. Vuorikoski, P. Bostrom, M. Laato, P.J. Bostrom and H. Jarvelainen (see also Biotechnology).

Keywords for this news article include: Biotechnology, Turku, Europe, Finland, Oncology, Therapeutics, Cancer Gene Therapy.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Gene Therapy Week


Story Tools